| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -29.12M | -98.91M | -105.40M | 47.91M | 101.98M | 60.29M |
| Gross Profit | -29.36M | -164.04M | -150.93M | -612.00K | 81.20M | 60.29M |
| EBITDA | -86.60M | -2.64B | -234.09M | -41.67M | -13.81M | -135.05M |
| Net Income | -78.12M | -2.10B | -130.98M | -95.02M | -58.04M | -334.04M |
Balance Sheet | ||||||
| Total Assets | 316.23M | 368.50M | 368.50M | 2.91B | 3.14B | 2.82B |
| Cash, Cash Equivalents and Short-Term Investments | 6.68M | 7.91M | 7.91M | 8.73M | 70.59M | 12.49M |
| Total Debt | 103.96M | 130.25M | 130.25M | 151.44M | 171.59M | 256.34M |
| Total Liabilities | 368.53M | 309.57M | 309.57M | 231.79M | 241.43M | 282.84M |
| Stockholders Equity | -222.89M | -234.35M | -234.35M | 1.59B | 1.44B | 621.50M |
Cash Flow | ||||||
| Free Cash Flow | -44.07M | -59.98M | -97.19M | -61.21M | -57.23M | -54.17M |
| Operating Cash Flow | -43.81M | -58.22M | -95.12M | -57.00M | -54.01M | -51.19M |
| Investing Cash Flow | 59.77M | 44.06M | 63.02M | 44.59M | -5.98M | 70.44M |
| Financing Cash Flow | -15.85M | 12.59M | -34.46M | 14.86M | 43.86M | -5.24M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
61 Neutral | $6.86M | -4.20 | -25.88% | 1.07% | 66.65% | -1497.99% | |
55 Neutral | $37.69M | 58.66 | 5.87% | ― | -37.08% | ― | |
48 Neutral | $5.51M | -0.01 | ― | ― | ― | ― | |
45 Neutral | $96.48M | -0.08 | ― | ― | -33.98% | 94.83% | |
42 Neutral | $9.04M | -0.08 | -1438.14% | ― | -62.09% | -99.89% | |
34 Underperform | $16.37M | -0.78 | -109.09% | ― | ― | 60.78% |
Beneficient announced that its Board of Directors appointed Peter T. Cangany Jr. as Chairman of the Board, effective December 15, 2025. Mr. Cangany brings decades of leadership in financial services, corporate governance, and financial reporting, having previously served as a director of Beneficient since 2019 and held senior leadership positions at Ernst & Young LLP for nearly 40 years. His appointment is expected to bolster Beneficient’s strategic approach and long-term shareholder value creation.
On December 1, 2025, Beneficient‘s stockholders approved a reverse stock split of its Class A and Class B common stock at a ratio of 1-for-8, which was subsequently approved by the Board of Directors to take effect on December 15, 2025. This move is intended to help Beneficient regain compliance with Nasdaq’s minimum bid price requirement. The reverse stock split will reduce the number of shares issued and outstanding and proportionally decrease the number of authorized shares, while increasing the exercise or conversion price per share. Beneficient’s Class A Common Stock will continue trading under the symbol ‘BENF’ on a split-adjusted basis starting December 15, 2025.
On December 10, 2025, Beneficient announced the passing of Thomas O. Hicks, Chairman of its Board of Directors, who died on December 6, 2025, at the age of 79. Hicks was a pioneering figure in private equity and had a significant impact on the company and the city of Dallas. Beneficient’s Board and management are committed to honoring his legacy by continuing to execute the company’s mission with the vision and courage he exemplified.
On December 1, 2025, Beneficient held a Special Meeting of Stockholders where approximately 92.8% of the company’s total voting power was represented. During this meeting, stockholders approved two key proposals: a reverse stock split of the company’s common stock at a ratio between 1-for-5 and 1-for-100, and an adjournment of the meeting if necessary to secure further proxy votes. These approvals are significant for Beneficient’s operational strategies and shareholder engagement.
On November 5, 2025, Beneficient announced the indictment of its former Chairman and CEO, Brad Heppner, by the United States Attorney for the Southern District of New York. Beneficient had previously parted ways with Heppner after discovering credible evidence of his fraudulent activities. The company is pursuing potential claims against him and is cooperating with the government’s investigation. These developments are seen as a step towards strengthening Beneficient’s foundation for growth and transparency, while maintaining its focus on delivering innovative liquidity and trust solutions for alternative asset holders.
On October 30, 2025, Beneficient announced it had regained compliance with Nasdaq’s periodic filing and market value of listed securities requirements. However, the company remains noncompliant with the $1.00 per share bid price requirement and plans to seek stockholder approval for a reverse stock split to address this issue within the extension period granted by the Nasdaq Hearings Panel.
On October 21, 2025, Beneficient announced a Limited Conversion of subsidiary securities into Class A Common Stock by its Chairman, Thomas O. Hicks, and Interim CEO, James G. Silk, totaling approximately $52.6 million. This conversion aims to better position the company for long-term success, address Nasdaq’s minimum stockholders’ equity requirement, and simplify its capital structure. The conversion aligns the interests of leadership with stockholders, as Hicks and Silk agreed to a lock-up period until October 2028, foregoing potential appreciation in share value during this time.
On October 3, 2025, Beneficient was notified by Nasdaq about non-compliance with the minimum stockholders’ equity requirement, which could lead to delisting. The company is actively working to meet compliance standards, including addressing issues related to periodic filing and bid price requirements, and plans to propose a reverse stock split to regain compliance.